CIK 0001358762
RETA REATA PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing Mar 15, 2023.
In brief
REATA PHARMACEUTICALS INC (RETA) has 29 SEC Form 4 filings on file from 10 insiders, the latest filed on Mar 15, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
17 open-market trades have been scored at RETA. The newest: Dawn Carter Bir (Chief Commercial Officer) sold $808k of stock on Mar 13, 2023, filed Mar 15, 2023, scored 57 (moderate). The largest of the 17 shown: Dawn Carter Bir (Chief Commercial Officer) sold $8.5M on Mar 6, 2023, scored 60 (notable). 9 insiders sold within 14 days of each other around Mar 13, 2023.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at REATA PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Dawn Carter Bir Chief Commercial Officer sell | $808k 9,317 shares | -22% | - | |
| 53Moderate | Shamim Ruff director sell | $481k 5,740 shares | -52% | - | |
| 50Moderate | Andrea Loewen SVP, Global Regulatory Affairs sell | $1.6M 19,036 shares | -33% | - | |
| 30Weak | Bhaskar Anand SVP, Chief Accounting Officer sell | $14k 165 shares | -1% | - | |
| 60Notable | Dawn Carter Bir Chief Commercial Officer sell | $8.5M 96,996 shares | -100% | - | |
| 45Moderate | Samina Khan SVP, Chief Medical Officer sell | $331k 3,961 shares | -9% | - | |
| 37Weak | Colin John Meyer Chief Innovation Officer sell | $53k 621 shares | -1% | - | |
| 36Weak | Michael D Wortley Chief Legal Officer sell | $35k 414 shares | -1% | - | |
| 44Moderate | Manmeet Singh Soni COO, CFO and President sell | $53k 622 shares | -1% | - | |
| 38Weak | Bhaskar Anand SVP, Chief Accounting Officer sell | $72k 820 shares | -3% | - | |
| 42Moderate | Dawn Carter Bir Chief Commercial Officer sell | $191k 2,166 shares | -4% | - | |
| 50Moderate | Samina Khan SVP, Chief Medical Officer sell | $2.4M 27,813 shares | -39% | - | |
| 41Moderate | Andrea Loewen SVP, Global Regulatory Affairs sell | $160k 1,819 shares | -4% | - | |
| 60Notable | Colin John Meyer Chief Innovation Officer sell | $8.1M 93,922 shares | -52% | - | |
| 51Moderate | Manmeet Singh Soni COO, CFO and President sell | $316k 3,587 shares | -4% | - | |
| 42Moderate | Michael D Wortley Chief Legal Officer sell | $190k 2,169 shares | -4% | - | |
| 85Strong | James Warren Huff Chief Executive Officer sell | $6.4M 75,000 shares | -67% | - |
Transactions
The newest 50 of 87 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2023 | Dawn Carter Bir Chief Commercial Officer | SOpen-market sale Class A common stock | -9,317 | $86.77 | $808k | 32,196 | Mar 15, 2023 |
| Mar 10, 2023 | Shamim Ruff director | MOption exercise Class A common stock | +199 | $27.32 | $5,437 | 5,422 | Mar 13, 2023 |
| Mar 10, 2023 | Shamim Ruff director | MOption exercise Class A common stock | +1,326 | $34.76 | $46k | 6,748 | Mar 13, 2023 |
| Mar 10, 2023 | Shamim Ruff director | MOption exercise Class A common stock | +4,215 | $34.76 | $147k | 10,963 | Mar 13, 2023 |
| Mar 10, 2023 | Shamim Ruff director | SOpen-market sale Class A common stock | -5,740 | $83.73 | $481k | 5,223 | Mar 13, 2023 |
| Mar 10, 2023 | Shamim Ruff director | MOption exercise Stock Option (right to buy)derivative | -199 | $0.00 | $0 | 0 | Mar 13, 2023 |
| Mar 10, 2023 | Shamim Ruff director | MOption exercise Stock Option (right-to-buy)derivative | -1,326 | $0.00 | $0 | 443 | Mar 13, 2023 |
| Mar 10, 2023 | Shamim Ruff director | MOption exercise Stock Option (right-to-buy)derivative | -4,215 | $0.00 | $0 | 1,405 | Mar 13, 2023 |
| Mar 7, 2023 | Andrea Loewen SVP, Global Regulatory Affairs | MOption exercise Class A common stock | +15,000 | $27.32 | $410k | 57,793 | Mar 9, 2023 |
| Mar 7, 2023 | Andrea Loewen SVP, Global Regulatory Affairs | SOpen-market sale Class A common stock | -17,836 | $83.36 | $1.5M | 39,957 | Mar 9, 2023 |
| Mar 7, 2023 | Andrea Loewen SVP, Global Regulatory Affairs | SOpen-market sale Class A common stock | -1,200 | $84.44 | $101k | 38,757 | Mar 9, 2023 |
| Mar 7, 2023 | Andrea Loewen SVP, Global Regulatory Affairs | MOption exercise Employee Stock Option (right to buy)derivative | -15,000 | $0.00 | $0 | 35,000 | Mar 9, 2023 |
| Mar 7, 2023 | Michael D Wortley Chief Legal Officer | SOpen-market sale Class A common stock | -414 | $84.46 | $35k | 48,092 | Mar 8, 2023 |
| Mar 7, 2023 | Samina Khan SVP, Chief Medical Officer | SOpen-market sale Class A common stock | -3,961 | $83.46 | $331k | 40,131 | Mar 8, 2023 |
| Mar 7, 2023 | Bhaskar Anand SVP, Chief Accounting Officer | SOpen-market sale Class A common stock | -165 | $84.58 | $14k | 26,765 | Mar 8, 2023 |
| Mar 7, 2023 | Colin John Meyer Chief Innovation Officer | SOpen-market sale Class A common stock | -621 | $84.57 | $53k | 84,606 | Mar 8, 2023 |
| Mar 7, 2023 | Manmeet Singh Soni COO, CFO and President | SOpen-market sale Class A common stock | -622 | $84.70 | $53k | 88,304 | Mar 8, 2023 |
| Mar 6, 2023 | Dawn Carter Bir Chief Commercial Officer | CConversion Class A common stock | +48,370 | - | - | 96,879 | Mar 8, 2023 |
| Mar 6, 2023 | Dawn Carter Bir Chief Commercial Officer | SOpen-market sale Class A common stock | -40,134 | $89.30 | $3.6M | 56,745 | Mar 8, 2023 |
| Mar 6, 2023 | Dawn Carter Bir Chief Commercial Officer | SOpen-market sale Class A common stock | -14,820 | $90.26 | $1.3M | 41,925 | Mar 8, 2023 |
| Mar 7, 2023 | Dawn Carter Bir Chief Commercial Officer | CConversion Class A common stock | +41,630 | - | - | 83,555 | Mar 8, 2023 |
| Mar 7, 2023 | Dawn Carter Bir Chief Commercial Officer | SOpen-market sale Class A common stock | -36,049 | $85.08 | $3.1M | 47,506 | Mar 8, 2023 |
| Mar 7, 2023 | Dawn Carter Bir Chief Commercial Officer | SOpen-market sale Class A common stock | -5,793 | $85.90 | $498k | 41,713 | Mar 8, 2023 |
| Mar 7, 2023 | Dawn Carter Bir Chief Commercial Officer | SOpen-market sale Class A common stock | -200 | $86.67 | $17k | 41,513 | Mar 8, 2023 |
| Mar 6, 2023 | Dawn Carter Bir Chief Commercial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -48,370 | $0.00 | $0 | 41,630 | Mar 8, 2023 |
| Mar 6, 2023 | Dawn Carter Bir Chief Commercial Officer | MOption exercise Class B common stockderivative | +48,370 | $21.05 | $1.0M | 48,370 | Mar 8, 2023 |
| Mar 6, 2023 | Dawn Carter Bir Chief Commercial Officer | CConversion Class B common stockderivative | -48,370 | - | - | 0 | Mar 8, 2023 |
| Mar 7, 2023 | Dawn Carter Bir Chief Commercial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -41,630 | $0.00 | $0 | 0 | Mar 8, 2023 |
| Mar 7, 2023 | Dawn Carter Bir Chief Commercial Officer | MOption exercise Class B common stockderivative | +41,630 | $21.05 | $876k | 41,630 | Mar 8, 2023 |
| Mar 7, 2023 | Dawn Carter Bir Chief Commercial Officer | CConversion Class B common stockderivative | -41,630 | - | - | 0 | Mar 8, 2023 |
| Mar 3, 2023 | R Kent McGaughy Jr director, owner | GGift Class A common stockindirect: See footnote | -33,217 | $0.00 | $0 | 0 | Mar 7, 2023 |
| Mar 3, 2023 | Dawn Carter Bir Chief Commercial Officer | SOpen-market sale Class A common stock | -2,166 | $88.25 | $191k | 48,509 | Mar 6, 2023 |
| Mar 3, 2023 | Manmeet Singh Soni COO, CFO and President | SOpen-market sale Class A common stock | -3,587 | $87.97 | $316k | 88,926 | Mar 6, 2023 |
| Mar 3, 2023 | Michael D Wortley Chief Legal Officer | SOpen-market sale Class A common stock | -2,169 | $87.57 | $190k | 48,506 | Mar 6, 2023 |
| Mar 2, 2023 | Andrea Loewen SVP, Global Regulatory Affairs | SOpen-market sale Class A common stock | -218 | $90.61 | $20k | 44,394 | Mar 6, 2023 |
| Mar 3, 2023 | Bhaskar Anand SVP, Chief Accounting Officer | SOpen-market sale Class A common stock | -820 | $87.47 | $72k | 26,930 | Mar 6, 2023 |
| Mar 2, 2023 | Colin John Meyer Chief Innovation Officer | CConversion Class A common stock | +88,636 | - | - | 179,149 | Mar 6, 2023 |
| Mar 2, 2023 | Samina Khan SVP, Chief Medical Officer | MOption exercise Class A common stock | +25,000 | $27.32 | $683k | 71,905 | Mar 6, 2023 |
| Mar 3, 2023 | Andrea Loewen SVP, Global Regulatory Affairs | SOpen-market sale Class A common stock | -1,601 | $87.73 | $140k | 42,793 | Mar 6, 2023 |
| Mar 2, 2023 | Samina Khan SVP, Chief Medical Officer | SOpen-market sale Class A common stock | -3,395 | $83.70 | $284k | 68,510 | Mar 6, 2023 |
| Mar 2, 2023 | Colin John Meyer Chief Innovation Officer | SOpen-market sale Class A common stock | -22,752 | $85.23 | $1.9M | 156,397 | Mar 6, 2023 |
| Mar 2, 2023 | Samina Khan SVP, Chief Medical Officer | SOpen-market sale Class A common stock | -18,956 | $85.02 | $1.6M | 49,554 | Mar 6, 2023 |
| Mar 2, 2023 | Colin John Meyer Chief Innovation Officer | SOpen-market sale Class A common stock | -34,794 | $86.49 | $3.0M | 121,603 | Mar 6, 2023 |
| Mar 2, 2023 | Colin John Meyer Chief Innovation Officer | SOpen-market sale Class A common stock | -19,099 | $87.55 | $1.7M | 102,504 | Mar 6, 2023 |
| Mar 2, 2023 | Samina Khan SVP, Chief Medical Officer | SOpen-market sale Class A common stock | -2,649 | $85.38 | $226k | 46,905 | Mar 6, 2023 |
| Mar 3, 2023 | Samina Khan SVP, Chief Medical Officer | SOpen-market sale Class A common stock | -2,813 | $87.36 | $246k | 44,092 | Mar 6, 2023 |
| Mar 2, 2023 | Colin John Meyer Chief Innovation Officer | SOpen-market sale Class A common stock | -11,181 | $88.50 | $990k | 91,323 | Mar 6, 2023 |
| Mar 2, 2023 | Colin John Meyer Chief Innovation Officer | SOpen-market sale Class A common stock | -810 | $90.58 | $73k | 90,513 | Mar 6, 2023 |
| Mar 2, 2023 | Samina Khan SVP, Chief Medical Officer | MOption exercise Employee Stock Option (right to buy)derivative | -25,000 | $0.00 | $0 | 25,000 | Mar 6, 2023 |
| Mar 3, 2023 | Colin John Meyer Chief Innovation Officer | SOpen-market sale Class A common stock | -5,286 | $87.35 | $462k | 85,227 | Mar 6, 2023 |
50 of 87 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Bhaskar AnandSVP, Chief Accounting Officer
- Dawn Carter BirChief Commercial Officer
- James Warren HuffChief Executive Officer
- Samina KhanSVP, Chief Medical Officer
- Andrea LoewenSVP, Global Regulatory Affairs
- R Kent McGaughy Jrdirector, owner
- Colin John MeyerChief Innovation Officer
- Shamim Ruffdirector
- Manmeet Singh SoniCOO, CFO and President
- Michael D WortleyChief Legal Officer
Questions about RETA
Answered from the filings on this page, as of the latest one.
Are insiders buying RETA?
No. In the last 90 days no insider at REATA PHARMACEUTICALS INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RETA on the open market?
Dawn Carter Bir (Chief Commercial Officer) sold $808k of RETA on Mar 13, 2023 and filed the Form 4 on Mar 15, 2023. InsiderTell scored 57 (moderate), with 9 insiders on the same side within 14 days.
How many insiders file Form 4 at REATA PHARMACEUTICALS INC?
10 people have filed a Form 4 at REATA PHARMACEUTICALS INC, among them Bhaskar Anand (SVP, Chief Accounting Officer), Dawn Carter Bir (Chief Commercial Officer), James Warren Huff (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.